Overcoming Endotoxin Test Interference in AAV Workflows

August 14, 2026

The Risk of Endotoxin Contamination of Adeno-Associated Virus (AAV) Vectors 

Gene therapy implements genetic techniques to deliver a functional gene copy or to restore a gene’s physiological function and has great potential for the treatment of a number of diseases. Adeno-associated virus (AAV) vectors are derived from non-pathogenic, replication-defective, non-enveloped parvovirus and can serve as an efficient gene delivery tool. The first AAV-based gene therapeutics have gained regulatory approvals in both the United States and Europe.

Like other pharmaceutical or biologic products, AAV-based therapeutics are at risk for endotoxin contamination. Endotoxins are potent pyrogens, which can elicit fever, inflammation, and septic shock if they get access to the cardiovascular or lymphatic systems, cerebrospinal fluid, or the intraocular environment. They are present in the outer membrane of gram-negative bacteria and are released into the environment primarily during bacterial cell lysis. As AAV-based therapies are generally delivered as parenteral injectables, they should be subjected to strict endotoxin testing. 

Principles of Endotoxin Testing 

The Limulus amebocyte lysate (LAL) assay has been widely accepted as a gold standard for endotoxin testing due to its high sensitivity and specificity. Accordingly, it has been adopted by the United States Pharmacopeia, the European Pharmacopoeia, and the Japanese Pharmacopoeia. The LAL test can be performed as a qualitative gel-clot assay or quantitative chromogenic or turbidimetric assays. Further, synthetic reagents for bacterial endotoxin testing, including recombinant Cascade Reagents (rCR) and recombinant Factor C Reagents (rFC), have been developed to reduce the need for horseshoe crab blood used in LAL reagent production. Currently, both rCR and rFC reagents are accepted within the United States Pharmacopeia. 

Challenges of Endotoxin Testing AAV Vectors 

The endotoxin testing of AAV vectors has its own challenges. For example, AAV manufacturing is prone to endotoxin contamination, making endotoxin testing for AAV-based parenteral injectables highly regulated. Moreover, as AAV vector-based products are typically manufactured on a small scale, standard testing schedules may not always be feasible. In addition, products derived from the AAV manufacturing process may interfere with the LAL test. 

The Value of Alternative Schedules for Endotoxin Testing AAV Vectors 

After ensuring the consistency of the manufacturing process, alternative endotoxin testing schedules should be considered by custom-production companies that manufacture AAV vectors and other gene therapy products on a small scale. The American National Standards Institute (ANSI) and the Association for the Advancement of Medical Instrumentation (AAMI) have set out guidelines for the design of in-process and end-product alternative endotoxin testing plans. Notably, alternative testing plans should be aligned with regulatory requirements, should consider key manufacturing steps, and should include a well-thought-out sampling plan. 

Development of Protocols for AAV Sample Decontamination 

Good Manufacturing Practice (GMP) strategies have been developed for the production of AAV vectors. In addition, protocols are being designed for the decontamination of concentrated AAV samples. When decontaminating AAV stocks, it is important to maintain the level of detergents below a critical threshold, because residual detergents can have a masking effect, causing interference with LAL reagents. 

The Potential of Low Endotoxin Strains of E. coli 

In addition, low endotoxin strains of E. coli have been proposed for plasmid DNA isolation as a strategy to decrease the level of endotoxins in AAV samples. This approach is reportedly scalable and can be used in both academic laboratories and for clinical development.

FUJIFILM Biosciences offers pyrogen and sterility testing solutions that enable consistent, scalable testing at every stage of development from upstream processing to final quality control and release. Discover how we can help you advance your testing strategy with solutions designed for today’s biologics.